WANBURYNSEWanbury Limited· PharmaceuticalsHighNeutral
Announced Mon, 4 Aug · 21:24 IST

Wanbury Limited has submitted to the Exchange, the financial results for the period ended Jun 30, 2025.

Revenue Growth 20pctPat Growth 25pctEbitda Margin ExpansionResults View source PDF

WANBURY · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reaction · full curve

Awaiting price reaction for this filing.

AI summary

Wanbury Limited reported unaudited Q1 FY26 (quarter ended June 30, 2025) results with revenue from operations of ₹163.18 crore, up roughly 24% from ₹131.11 crore in the same quarter last year. Profit after tax surged to ₹13.49 crore from just ₹1.04 crore a year ago — a more than 12-fold jump — helped by lower tax outflow and better operating margins. Basic EPS came in at ₹4.12 versus ₹0.32 in Q1 FY25. Apart from results, the board approved 91,500 stock options to employees under the ESOP 2016 scheme, re-appointed Whole-time Director Mr. Chandran Krishnamoorthy for another 5 years, and initiated the closure of three non-operational foreign subsidiaries in the Netherlands, China, and the UAE. The statutory auditor, Kapoor & Parekh Associates, issued an unmodified (clean) review report on both the standalone and consolidated numbers.

Likely market impact

Strong YoY revenue growth, a sharp rebound in profitability, and visible margin expansion are positive signals for shareholders. The low base of Q1 FY25 flatters the headline PAT growth, but finance costs remain elevated at ₹7.54 crore and warrant monitoring. The subsidiary closures are housekeeping with no impact on revenue, while the ESOP grant and director re-appointment are routine governance items.